| Overview |
| bs-10396R-BF647 |
| OPRD1 Polyclonal Antibody, AbBy Fluor® 647 Conjugated |
| WB, IF(IHC-P), IF(IHC-F), IF(ICC) |
| This antibody may also have a weak secondary cross-reaction with Mu-type opioid receptor, which is primarily expressed in the adrenal gland and testis. This is predicted based upon a 79% non-contiguous sequence similarity. |
| Human, Mouse, Rat |
| Dog, Cow, Pig, Chicken, Rabbit, Guinea Pig |
| Specifications |
| AbBy Fluor® 647 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human OPRD1 |
| 81-180/372 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 4985 |
| P41143 |
| Cell membrane |
| OPRD; Delta-type opioid receptor; D-OR-1; DOR-1; OPRD1 |
| G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurotransmitter release by reducing calcium ion currents and increasing potassium ion conductance. Plays a role in the perception of pain and in opiate-mediated analgesia. Plays a role in developing analgesic tolerance to morphine. |
| Application Dilution |
| WB |
1:300-5000 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz